• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Anti-inflammatory Agents Other Products
You are here: Product Lines > Inflammation > Anti-inflammatory Agents > Anti-inflammatory Agents Other Products
Toolbar - View Selection
 
Items 14 of 14
ALX-340-042 Revised 07-Jan-06
Arvanil
Add to Clipboard
SYNONYMS N-[(4-Hydroxy-3-methoxyphenyl)methyl]-5Z,8Z,11Z,14Z-eicosatetraenamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Cannabinoid Receptor Agonists & Antagonists / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-042-M005   5 mg 25.00 USD Add To Cart
Product Specification
FORMULA: C28H41NO3
MW: 439.6
CAS NUMBER: 128007-31-8
PURITY: ≥98%
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Protect from light. Keep cool and dry.

Product Description
"Hybrid" activator of CB1 receptor (CB1: Ki=0.5µM; CB2: Ki=>15µM) and TRPV1 (Ki=0.3µM). Also inhibits anandamide uptake (IC50=3.6µM) and fatty acid amide hydrolase (FAAH) (IC50=3µM). Analgesic, vasodilatory and anti-inflammatory in vivo. Apoptosis inducer.
Product Specific Literature References
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors: D. Melck, et al.; BBRC 262, 275 (1999) Abstract
Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide: V. Di Marzo, et al.; Eur. J. Pharmacol. 406, 363 (2000) Abstract
A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid: V. Di Marzo, et al.; J. Pharmacol. Exp. Ther. 300, 984 (2002) Abstract
The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway: R. Sancho, et al.; Br. J. Pharmacol. 140, 1035 (2003) Abstract
Evidence against the presence of an anandamide transporter: S.T. Glaser, et al.; PNAS 100, 4269 (2003) Abstract
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease: E. de Lago, et al.; Brain Res. 1050, 210 (2005) Abstract
Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis: A.M. Malfitano, et al.; J. Neuroimmunol. 171, 110 (2006) Abstract
 
 
ALX-270-443 Revised 05-May-08
AS601245
Add to Clipboard
SYNONYMS 1,3-Benzothiazol-2-yl-(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl) acetonitrile
JNK Inhibitor V
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY JNK [SAPK1] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-443-M001   1 mg 50.00 USD Add To Cart
ALX-270-443-M005   5 mg 150.00 USD Add To Cart
ALX-270-443-M025   25 mg 520.00 USD Add To Cart
Product Specification
FORMULA: C20H16N6S
MW: 372.5
CAS NUMBER: 345987-15-7
PURITY: ≥95% (HPLC)
APPEARANCE: White to yellow solid.
PURITY DETAIL: Sum of two isomers.
SOLUBILITY: Soluble in DMSO (10mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stock solutions are stable for up to 3 months when stored at -20°C.
HANDLING: Hygroscopic. Packaged under inert gas. Protect from light.
HAZARD: HARMFUL.
IDENTITY: Identity determined by 1H-NMR.

Product Description
Potent and cell permeable ATP competitive JNK inhibitor (hJNK1: IC50=150nM, hJNK2: IC50=220nM and hJNK3: IC50=70 nM). Displays anti-inflammatory properties and has been shown to reduce TNF-α plasma levels induced by LPS in mice.
Product Specific Literature References
AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties: S. Carboni, et al.; J. Pharmacol. Exp. Ther. 310, 25 (2004) Abstract; Full Text
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase: P. Gaillard, et al.; J. Med. Chem. 48, 4596 (2005) Abstract
 
 
ALX-430-064 Revised 15-Sep-08
Auranofin
Add to Clipboard
PRODUCT LINE Inflammation
PRODUCT CATEGORY Lipoxygenases / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-430-064-M025   25 mg 35.00 USD Add To Cart
ALX-430-064-M100   100 mg 68.00 USD Add To Cart
Product Specification
FORMULA: C20H34AuO9PS
MW: 678.5
CAS NUMBER: 34031-32-8
MERCK INDEX: 14: 878
PURITY: ≥98%
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in DMSO (5mg/ml) or 100% ethanol (4mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: +20°C
USE/STABILITY: Solutions are stable for up to 3 months when stored at -20 °C.
HAZARD: TOXIC.

Product Description
Gold derivative in clinical use as an anti-arthritic. Acts as an inhibitor of several leukocyte activation pathways. Inhibits release of inflammatory mediators from human macrophages, pulmonary mast cell and basophils. Also inhibits human neutrophil 5-lipoxygenase. Efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions, potentially referable to its inhibition of mitochondrial thioredoxin reductase.
Product Specific Literature References
Antiarthritic gold compounds effectively quench electronically excited singlet oxygen: E.J. Corey, et al.; Science 236, 68 (1987) Abstract
Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin: M. Columbo, et al.; Biochem. Pharmacol. 39, 285 (1990) Abstract
Auranofin stimulates LTA hydrolase and inhibits 5-lipoxygenase/LTA synthase activity of isolated human neutrophils: W.H. Betts, et al.; Biochem. Pharmacol. 39, 1233 (1990) Abstract
Auranofin inhibits the activation pathways of polymorphonuclear leukocytes at multiple sites: R. Rudkowski, et al.; Biochem. Pharmacol. 41, 1921 (1991) Abstract
Induction of mitochondrial permeability transition by auranofin, a Gold(I)-phosphine derivative: M.P. Rigobello, et al.; Br. J. Pharmacol. 136, 1162 (2002) Abstract
General Literature References
Auranofin: W.F. Kean, et al.; Br. J. Theumatol. 36, 560 (1997), (Review) Abstract; Full Text
 
 
ALX-270-219 Revised 15-May-07
BAY 11-7082
Add to Clipboard
SYNONYMS (E)-3-(4-Methylphenylsulfonyl)-2-propenenenitrile
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY NF-kB Pathway Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-219-M010   10 mg 45.00 USD Add To Cart
ALX-270-219-M050   50 mg 190.00 USD Add To Cart
Product Specification
FORMULA: C10H9NO2S
MW: 207.3
CAS NUMBER: 195462-67-7
PURITY: ≥99%
SOLUBILITY: Soluble in DMSO, 100% ethanol, methanol or methylene dichloride; insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light. Keep under inert gas.

Product Description
Inhibitor of cytokine induced IκBα phosphorylation resulting thereby in a decreased expression of NF-κB and adhesion molecules. Potential anti-inflammatory agent.
Product Specific Literature References
Novel inhibitor of cytokine-induced IkBa phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo: J.W. Pierce, et al.; J. Biol. Chem. 272, 21096 (1997) Abstract; Full Text
Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells: S.A. Keller, et al.; Blood 96, 2537 (2000) Abstract
Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha- induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways: M.M. Remacle-Bonnet, et al.; Cancer Res. 60, 2007 (2000) Abstract
Up-regulation of multidrug resistance P-glycoprotein via nuclear factor- kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis: F. Thevenod, et al.; J. Biol. Chem. 275, 1887 (2000) Abstract; Full Text
Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: nuclear factor kappaB inhibitors reduce basal and lesion-induced secretion of apolipoprotein E: V. Petegnief, et al.; Neuroscience 104, 223 (2001) Abstract
Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death: T.M. Kauppinen & R.A. Swanson; J. Immunol. 174, 2288 (2005) Abstract; Full Text
Further Categories Containing This Product:
Anti-inflammatory Agents Other Products
 
 
ALX-270-220 Revised 04-Nov-05
BAY 11-7085
Add to Clipboard
SYNONYMS (E)-3-(t-Butylphenylsulfonyl)-2-propenenitrile
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY NF-kB Pathway Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-220-M010   10 mg 60.00 USD Add To Cart
Product Specification
FORMULA: C13H15NO2S
MW: 249.3
CAS NUMBER: 196309-76-9
PURITY: ≥98%
APPEARANCE: White to off-white crystalline powder.
SOLUBILITY: Soluble in DMSO or ethanol; insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light. Keep under inert gas.

Product Description
Has biological properties very similar to those of BAY 11-7082 (Prod. No. ALX-270-219). In addition, the product exhibits potent anti-inflammatory properties in vivo.
Product Specific Literature References
Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo: J.W. Pierce, et al.; J. Biol. Chem. 272, 21096 (1997) Abstract; Full Text
Pharmacologic interference with NF-kappaB activation attenuates central nervous system complications in experimental Pneumococcal meningitis: U. Koedel, et al.; J. Infect Dis. 182, 1437 (2000) Abstract
Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: nuclear factor kappaB inhibitors reduce basal and lesion-induced secretion of apolipoprotein E: V. Petegnief, et al.; Neuroscience 104, 223 (2001) Abstract
Further Categories Containing This Product:
Anti-inflammatory Agents Other Products
 
 
ALX-270-097 Revised 07-Sep-06
Ebselen
Add to Clipboard
SYNONYMS 2-Phenyl-1,2-benzisoselenazol-3-(2H)-one
PRODUCT LINE Oxidative Stress
PRODUCT CATEGORY Peroxynitrite / Scavengers / Detection
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-097-M001   1 mg 12.00 USD Add To Cart
ALX-270-097-M005   5 mg 20.00 USD Add To Cart
ALX-270-097-M025   25 mg 60.00 USD Add To Cart
Product Specification
FORMULA: C13H9NOSe
MW: 274.2
CAS NUMBER: 60940-34-3
PURITY: ≥98% (NMR)
APPEARANCE: White to off-white crystalline solid.
SOLUBILITY: Soluble in DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description
Selenium-based inhibitor of protein kinase C, NADPH, 5-lipoxygenase, cyclooxygenase (COX) and NADPH oxidase. Anti-inflammatory antioxidant. Mimics glutathione peroxidase. Inhibits oxidative modifications of low density lipoproteins (LDL).
Product Specific Literature References
A novel biologically active seleno-organic compound--III. Effects of PZ 51 (Ebselen) on glutathione peroxidase and secretory activities of mouse macrophages: M.J. Parnham & S. Kindt; Biochem. Pharmacol. 33, 3247 (1984) Abstract
Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions: M.J. Parnham & E. Graf; Biochem. Pharmacol. 36, 3095 (1987) Abstract
Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51): M. Maiorino, et al.; Biochem. Pharmacol. 37, 2267 (1988) Abstract
Studies on the anti-inflammatory activity of ebselen. Ebselen interferes with granulocyte oxidative burst by dual inhibition of NADPH oxidase and protein kinase C?: I.A. Cotgreave, et al.; Biochem. Pharmacol. 38, 649 (1989) Abstract
T. Nikawa, et al.; Biochem. Pharmacol. 47, 1007 (1994) Abstract
Effects of ebselen and probucol on oxidative modifications of lipid and protein of low density lipoprotein induced by free radicals: N. Noguchi, et al.; Biochim. Biophys. Acta 1213, 176 (1994) Abstract
Strong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione: C. Schewe, et al.; Biochem. Pharmacol. 48, 65 (1994) Abstract
Ebselen: a glutathione peroxidase mimic: H. Sies; Meth. Enzymol. 234, 476 (1994) Abstract
Molecular actions of ebselen-an antiinflammatory antioxidant: T. Schewe; Gen. Pharmacol. 26, 1153 (1995) Abstract
Ebselen: H. Sies; Meth. Enzymol. 252, 341 (1995) Abstract
Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite: H. Sies & H. Masumoto; Adv. Pharmacol. 38, 229 (1997) Abstract
Free radical generation by selenium compounds and their prooxidant toxicity: J.E. Spallholz; Biomed. Environ. Sci. 10, 260 (1997) Abstract
Protection against peroxynitrite by selenoproteins: H. Sies, et al.; Z. Naturforsch. [C] 53, 228 (1998) Abstract
Ebselen protects mice against T cell-dependent, TNF-mediated apoptotic liver injury: G. Tiegs, et al.; J. Pharmacol. Exp. Ther. 287, 1098 (1998) Abstract; Full Text
 
 
ALX-350-254 Revised 10-Mar-08
Epoxomicin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Proteasome / Ubiquitin Modulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-254-C050   50 µg 132.00 USD Add To Cart
Product Specification
FORMULA: C28H50N4O7
MW: 554.7
CAS NUMBER: 134381-21-8
MERCK INDEX: 14: 3630
SOURCE/HOST: Synthetic.
PURITY: ≥95% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO (15mg/ml); insoluble in water.
ACTIVITY: kobs/[I] = 25’000M-1s-1 versus 20S proteasome.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles. Protect from light.
IDENTITY: Identity determined by 1H-NMR.

Product Description
Cell permeable, potent and selective proteasome inhibitor originally isolated from Actinomycetes strain based on its potent in vivo antitumor activity. More potent inhibitor of the chymotrypsin-like activity of the proteasome than lactacystin. Effectively inhibits NF-κB activation in vitro and potently blocks inflammation in vivo in the mouse ear edema assay.
Product Specific Literature References
Epoxomicin, a new antitumor agent of microbial origin: M. Hanada, et al.; J. Antibiot. (Tokyo) 45, 1746 (1992) Abstract
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency: K.B. Kim, et al.; Bioorg. Med. Chem. Lett. 9, 3335 (1999) Abstract
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity: L. Meng, et al.; PNAS 96, 10403 (1999) Abstract
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology: N. Sin, et al.; Bioorg. Med. Chem. Lett. 9, 2283 (1999) Abstract
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses: K. Schwarz, et al.; J. Immunol. 164, 6147 (2000) Abstract
Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431: K. Ohkawa, et al.; Int. J. Oncol. 24, 425 (2004) Abstract
 
 
ALX-380-274 Revised 21-May-08
Erythromycin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics for Inflammation Research
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-274-G005   5 g 40.00 USD Add To Cart
Product Specification
FORMULA: C37H67NO13
MW: 733.9
CAS NUMBER: 114-07-8
MERCK INDEX: 14: 3681
RTECS: KF4375000
SOURCE/HOST: Isolated from Streptomyces erythreus.
PURITY: ≥85% (Assay on dry basis)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in water (50mg/ml), 100% ethanol or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HAZARD: HARMFUL.

Product Description
Macrolide antibiotic. Inhibits protein synthesis (elongation) at the transpeptidation step. Binds to the 23S RNA of the 50S ribosomal subunit. Effective against Gram-negative and Gram-positive bacteria.
Product Specific Literature References
Inducible erythromycin resistance in bacteria: B. Weisblum; Br. Med. Bull. 40, 47 (1984) Abstract
Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells: Y. Aoki & P.N. Kao; Antimicrob. Agents Chemother. 43, 2678 (1999) Abstract; Full Text
Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban: J.Q. Tran, et al.; J. Clin. Pharmacol. 39, 513 (1999) Abstract
Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism: T. Tokairin, et al.; Br. J. Clin. Pharmacol. 60, 172 (2005) Abstract; Full Text
Related Products
 
 
ALX-270-361 Revised 28-Sep-07
Indirubin
Add to Clipboard
PRODUCT LINE Cell Cycle
PRODUCT CATEGORY CDK & Cyclin Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-361-M001   1 mg 50.00 USD Add To Cart
ALX-270-361-M005   5 mg 200.00 USD Add To Cart
Product Specification
FORMULA: C16H10N2O2
MW: 262.3
CAS NUMBER: 479-41-4
SOURCE/HOST: Synthetic.
PURITY: ≥98% (1H-NMR, HPLC)
APPEARANCE: Purple powder.
SOLUBILITY: Soluble in DMSO (10mg/ml) or methanol (0.3mg/ml). Sparingly soluble in aqueous buffers (12.5µg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
USE/STAB